3

3-D Matrix Ltd
TSE:7777

Watchlist Manager
3-D Matrix Ltd
TSE:7777
Watchlist
Price: 453 JPY -2.37% Market Closed
Market Cap: ¥54.5B

Relative Value

The Relative Value of one 3-D Matrix Ltd stock under the Base Case scenario is hidden JPY. Compared to the current market price of 453 JPY, 3-D Matrix Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

3-D Matrix Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
3-D Matrix Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
3-D Matrix Ltd
TSE:7777
54.5B JPY 6.4 8 420.6 -206 -206
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
389.3B USD 6.5 165.8 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
187.3B USD 5.2 26.7 19.1 19.1
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD 5.9 21 14.2 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD 10.3 33 24.3 25.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD 5.6 17.5 16.7 18.9
AU
CSL Ltd
ASX:CSL
88.6B AUD 3.9 20.2 9.2 11.5
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.9 32.7 66.2 68
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD 14.9 1 095.4 147.6 179
P/S Multiple
Revenue Growth P/S to Growth
JP
3
3-D Matrix Ltd
TSE:7777
Average P/S: 3 068 053
6.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.9
5%
0.8
NL
argenx SE
XBRU:ARGX
13.9
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.9
47%
0.3
P/E Multiple
Earnings Growth PEG
JP
3
3-D Matrix Ltd
TSE:7777
Average P/E: 1 092.6
8 420.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.7
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
33
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.8
AU
CSL Ltd
ASX:CSL
20.2
11%
1.8
NL
argenx SE
XBRU:ARGX
32.7
42%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 095.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
3
3-D Matrix Ltd
TSE:7777
Average EV/EBITDA: 39.2
Negative Multiple: -206
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
19.1
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
7%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
11%
1.5
AU
CSL Ltd
ASX:CSL
9.2
8%
1.2
NL
argenx SE
XBRU:ARGX
66.2
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
147.6
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
3
3-D Matrix Ltd
TSE:7777
Average EV/EBIT: 44.9
Negative Multiple: -206
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
19.1
20%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
11.5
11%
1
NL
argenx SE
XBRU:ARGX
68
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
179
N/A N/A